Dimopoulos Highlights Benefit of Elotuzumab Triplet in Relapsed/Refractory Myeloma
July 2nd 2019
Meletios A. Dimopoulos, MD, discusses where the triplet combination of elotuzumab (Empliciti), pomalidomide (Pomalyst), and low-dose dexamethasone fits into the treatment paradigm of relapsed/refractory multiple myeloma and shared unanswered questions that remain in the space.